Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Zai Lab Expands into Pre-Clinical Research with Shanghai R&D Facility

publication date: Oct 23, 2015
Zai Lab, a two-year-old Shanghai innovative drug company, has opened a preclinical drug R&D center in Zhangjiang Hi-Tech Park, where it expects to discover and develop novel drugs for China and global markets. To date, Zai has in-licensed four clinical stage drug candidates from western pharmas. Now, the company will become an integrated pharmaceutical organization. At the same time, Zai announced a strategic alliance with Tsinghua University Immunology Institute, which will add drug candidates to Zai's portfolio of cancer and immunology candidates. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital